

TABLE OF CONTENTS

ABBREVIATIONS	i-vii
1. INTRODUCTION	1-10
Epigenetics and cancer	3
BRCA1 gene	6
p16 gene	7
E-cadherin gene	7
HIC1 gene	8
GST-pi gene	9
Objectives	10
2. REVIEW OF LITERATURE	11-59
2.1. Cancer	11
2.1.1 Global Scenario	11
2.1.2 Indian Scenario	13
2.2 Breast Cancer	14
2.2.1 Global Scenario	14
2.2.2 Indian Scenario	16
2.3 Classification of breast tumors	18
2.3.1 Noninvasive Breast Cancers	19
2.3.2 Invasive Breast Cancers	19
2.4 Risk Factors of Breast Cancer	19
2.4.1 Non-Genetic Factors	20
2.4.1.1 Socioeconomic status	20
2.4.1.2 Smoking	20
2.4.1.3 Dietary Factors	20
2.4.1.4 Benign Breast Disease	21
2.4.1.5 Menarche and Menopause	21
2.4.1.6 Obesity	21
2.4.1.7 Pregnancy	21
2.4.1.8 Environmental Factors	22
2.4.1.9 Oral Contraceptives/ HRT	22
2.4.2 Genetic Factors	22

2.4.2.1	Genetic Alterations	23
2.4.2.2	Family History	23
2.5	Prevention of Breast Cancer	23
2.5.1	Primary Prevention	23
2.5.2	Secondary Prevention	24
2.5.3	Signs and Symptoms of Breast Cancer	24
2.5.4	Treatment of Breast Cancer	24
2.6	Staging of Breast Cancer	25
2.6.1	Clinical Staging	25
2.6.2	Pathological Staging	25
2.6.2.1	TNM Classification	26
2.6.3	Histopathological Grading	27
2.6.4	Lymph Node Metastasis	28
2.7	Hereditary Breast Cancer	29
2.8	Sporadic Breast Cancer	29
2.9	Hormonal Factors and Breast Cancer	30
2.10	Genes Involved In Breast Cancer	31
2.10.1	Tumor Suppressor Genes	32
2.10.1.1	Breast Cancer Susceptibility Gene 1 (BRCA1)	32
2.10.1.2	Breast Cancer Susceptibility Gene 2 (BRCA2)	33
2.10.1.3	p53 Tumor Suppressor Gene	34
2.10.1.4	P16 INK4a Tumor Suppressor Gene	35
2.10.1.5	E-cadherin Gene	36
2.10.2	Proto-oncogene	37
2.10.3	DNA Repair genes	38
2.10.3.1	HIC-1 Gene	38
2.10.3.2	GSTPi Gene	45
2.11	Epigenetics	46
2.11.1	DNA Methylation	47
2.11.2	DNA Methyltransferases	48
2.11.3	How methylation represses transcription	51
2.12	Epigenetic alterations in Cancer	53
2.12.1	DNA Methylation and Cancer	53
2.12.2	Hypermethylation and Gene Silencing	53
2.12.3	Hypomethylation and Gene Activation	55

2.13	Methods of Studying Methylation	57
2.13.1	Bisulfite Modification	58
2.13.2	Methylation Specific Polymerase Chain Reaction	58
3.	MATERIALS AND METHODS	60-71
3.1	General Chemicals	60
3.2.	Blotting membranes and Films	60
3.3	Plastic ware and glassware	60
3.4	Antibodies, Oligonucleotides and Enzymes	61
3.5	Biological Specimens	61
3.5.1	Tissue Biopsies	61
3.6	Methods	62
3.6.1	DNA Isolation from Breast Cancer Tissue Specimens	62
3.6.2	Quantitation of Genomic DNA using Agarose Gel Electrophoresis	63
3.6.3	Sodium Bisuphite Modification of DNA	63
3.6.4	Methylation Specific Polymerase Chain Reaction (MSP)	64
3.6.5	Preparation of Protein Extract	65
3.6.6	Western Blotting and ECL Detection	67
3.6.6.1	SDS-Poly-acrylamide Gel Electrophoresis	67
3.6.6.2	Immunoblotting-Semi-dry Transfer and ECL Detection	68
3.6.6.3	Blocking and Antibody Interaction	69
3.6.6.4	Enhanced Chemiluminescence (ECL) Detection	69
3.6.7	Immuno-histochemistry (IHC)	70
3.6.8	Statistical Analysis	71
	RESULTS	72-120
4.	Clinico-pathological attributes	72
4.1	Type of breast cancer	72
4.2	Age distribution	72
4.3	Menstrual status	72
4.4	Clinical Staging	72
4.5	Lymph Node status	73

4.6	Histopathological Grading	73
4.7	Hormonal Receptor Status	73
5.	Analysis of promoter hypermethylation pattern in specific tumor suppressor genes in sporadic breast carcinogenesis using methylation specific PCR (MSP)	75
5.1	Quality and quantity of genomic DNA	75
5.2	Methylation pattern of BRCA1, p16, GSTP1, HIC1 and CDH1 genes	76
6.	Comparison of gene methylation pattern with patient's clinicopathological attributes	79
6.1	Methylation pattern relative to patient menopausal status	79
6.2	Promoter methylation status relative to T-stage	80
6.3	Promoter methylation status relative to nodal status	80
6.4	Promoter methylation status relative to ER status	81
6.5	Promoter methylation status relative to PR status	85
6.6	Promoter methylation status relative to HER2/neu status	89
7.	Analysis of expression pattern of brca1, p16, GSTP1, HIC1 and CDH1 proteins in breast cancer patients	97
8.	<i>In-situ</i> expression profile of BRCA1, p16, GSTP1, HIC1 and CDH1 proteins	107
8.1	Comparison of in situ expression level with menopausal status	114
8.2	Comparison of in situ expression level with patient's tumor stage	115
8.3	Comparison of in situ expression level with lymph node status	115
8.4	Comparison of in situ expression level with ER status	116
8.5	Comparison of in situ expression level with PR status	117
8.6	Comparison of in situ expression level with HER2/neu status	118
8.7	Comparison of promoter methylation of five specific genes between Triple negative and triple positive breast tumors	119
8.8	Comparison of promoter methylation of five specific genes between ER/PR positive and ER/PR positive breast tumors	120
	DISCUSSION	121-143
	SUMMARY	144-148
	CONCLUSION	149-150
	REFERENCES	151-177
	ANNEXURES	